Wittert Gary A, Chapman Ian M, Haren Matthew T, Mackintosh Shylie, Coates Penelope, Morley John E
Department of Medicine, University of Adelaide, Royal Adelaide Hospital, Australia.
J Gerontol A Biol Sci Med Sci. 2003 Jul;58(7):618-25. doi: 10.1093/gerona/58.7.m618.
Loss of muscle mass (sarcopenia) leads to frailty in older men. The decline in testosterone over the life span may contribute to this muscle loss. We studied the ability of oral testosterone to prevent muscle loss in older men over a 12-month period.
A standard dose (80 mg twice daily) of testosterone undecanoate or placebo was administered for 1 year to 76 healthy men aged 60 years or older. All men had a free testosterone index of 0.3-0.5, which represents a value below the normal lower limit for young men (19-30 years), but remains within the overall normal male range. Measurements of body composition, muscle strength, hormones, and safety parameters were obtained at 0, 6, and 12 months.
Lean body mass increased (p =.0001) and fat mass decreased (p =.02) in the testosterone as compared with the placebo-treated group. There were no significant effects on muscle strength. There was a significant increase in hematocrit (0.02%) in the testosterone-treated group (p =.03). Plasma triglycerides, total cholesterol, and low-density lipoprotein cholesterol levels were similar in both groups, but there was a decrease in high-density lipoprotein cholesterol (-0.1 mmol/L) at 12 months in the testosterone group as compared to the placebo group (p = 0.026). There were no differences in prostate-specific antigen or systolic or diastolic blood pressure between the groups.
Oral testosterone administration to older relatively hypogonadal men results in an increase in muscle mass and a decrease in body fat.
肌肉量减少(肌肉减少症)会导致老年男性身体虚弱。一生中睾酮水平的下降可能是导致这种肌肉量减少的原因之一。我们研究了口服睾酮在12个月期间预防老年男性肌肉量减少的能力。
对76名60岁及以上的健康男性给予标准剂量(每日两次,每次80毫克)的十一酸睾酮或安慰剂,为期1年。所有男性的游离睾酮指数为0.3 - 0.5,该值低于年轻男性(19 - 30岁)的正常下限,但仍在男性总体正常范围内。在第0、6和12个月时测量身体成分、肌肉力量、激素和安全参数。
与安慰剂治疗组相比,接受睾酮治疗的组瘦体重增加(p = 0.0001),脂肪量减少(p = 0.02)。对肌肉力量无显著影响。睾酮治疗组的血细胞比容显著增加(0.02%)(p = 0.03)。两组的血浆甘油三酯、总胆固醇和低密度脂蛋白胆固醇水平相似,但与安慰剂组相比,睾酮组在12个月时高密度脂蛋白胆固醇水平下降(-0.1 mmol/L)(p = 0.026)。两组之间前列腺特异性抗原或收缩压或舒张压无差异。
对相对性腺功能减退的老年男性口服睾酮可导致肌肉量增加和体脂减少。